Aquoral oral spray that is indicated for the lubrication and protection of the oral mucosa in xerostomia (dry mouth), a common side-effect of chemotherapy and radiotherapy.

The launch adds another product to the oncology products commercial portfolio.

Other products in the portfolio include: Aloxi – for the prevention of chemotherapy induced nausea and vomiting, Episil – for the pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment.

IS Pharma CEO Tim Wright said that the commercial launch of Aquoral in the UK is a further step in the successful implementation of our strategy of building and maintaining a fast growing and profitable specialist pharmaceutical company through the acquisition and growth of specialist hospital medicines.